Improvement in RFS for atezolizumab plus bevacizumab vs active surveillance without compromising QoL

Prof Masatoshi Kudo speaks to ecancer at ASCO 2023 about the results from the phase III IMbrave050 trial of adjuvant atezolizumab plus bevacizumab vs active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation. He reports that atezolizumab plus bevacizumab showed significant improvement over surveillance with a 12 month recurrence-free survival of 78% vs 65%. Prof Kudo also explains that patient reported outcomes of quality of life was not deteriorated for atezolizumab plus bevacizumab in comparison with surveillance. Sign up to ecancer for free to receive tailored email alerts for more videos like this. ecancer.org/account/register.php